Search

Your search keyword '"Cornely, Oliver A."' showing total 3,056 results
Start Over Author "Cornely, Oliver A."
3,056 results on '"Cornely, Oliver A."'

4. Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author

Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

6. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author

Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

7. Early combination therapy of COVID-19 in high-risk patients

Author

Orth, Hans Martin, Flasshove, Charlotte, Berger, Moritz, Hattenhauer, Tessa, Biederbick, Kaja D., Mispelbaum, Rebekka, Klein, Uwe, Stemler, Jannik, Fisahn, Matthis, Doleschall, Anna D., Baermann, Ben-Niklas, Koenigshausen, Eva, Tselikmann, Olga, Killer, Alexander, de Angelis, Clara, Gliga, Smaranda, Stegbauer, Johannes, Spuck, Nikolai, Silling, Gerda, Rockstroh, Jürgen K., Strassburg, Christian P., Brossart, Peter, Panse, Jens P., Jensen, Björn-Erik Ole, Luedde, Tom, Boesecke, Christoph, Heine, Annkristin, Cornely, Oliver A., and Monin, Malte B.

Published
2024
Full Text
View/download PDF

8. Social determinants of health as drivers of fungal disease.

Author

Jenks, Jeffrey, Prattes, Juergen, Wurster, Sebastian, Sprute, Rosanne, Seidel, Danila, Oliverio, Matteo, Egger, Matthias, Del Rio, Carlos, Sati, Hatim, Cornely, Oliver, Thompson, George, Kontoyiannis, Dimitrios, and Hoenigl, Martin

Subjects
Fungal infections, Health care access, Social determinants of health, Structural conflict, Working conditions
Abstract

Disparities in social determinants of health (SDOH) play a significant role in causing health inequities globally. The physical environment, including housing and workplace environment, can increase the prevalence and spread of fungal infections. A number of professions are associated with increased fungal infection risk and are associated with low pay, which may be linked to crowded and sub-optimal living conditions, exposure to fungal organisms, lack of access to quality health care, and risk for fungal infection. Those involved and displaced from areas of armed conflict have an increased risk of invasive fungal infections. Lastly, a number of fungal plant pathogens already threaten food security, which will become more problematic with global climate change. Taken together, disparities in SDOH are associated with increased risk for contracting fungal infections. More emphasis needs to be placed on systematic approaches to better understand the impact and reducing the health inequities associated with these disparities.

Published
2023

9. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

Author

Bassetti, Matteo, Giacobbe, Daniele R., Agvald-Ohman, Christina, Akova, Murat, Alastruey-Izquierdo, Ana, Arikan-Akdagli, Sevtap, Azoulay, Elie, Blot, Stijn, Cornely, Oliver A., Cuenca-Estrella, Manuel, de Lange, Dylan W., De Rosa, Francesco G., De Waele, Jan J., Dimopoulos, George, Garnacho-Montero, Jose, Hoenigl, Martin, Kanj, Souha S., Koehler, Philipp, Kullberg, Bart J., Lamoth, Frédéric, Lass-Flörl, Cornelia, Maertens, Johan, Martin-Loeches, Ignacio, Muñoz, Patricia, Poulakou, Garyphallia, Rello, Jordi, Sanguinetti, Maurizio, Taccone, Fabio S., Timsit, Jean-François, Torres, Antoni, Vazquez, Jose A., Wauters, Joost, Asperges, Erika, Cortegiani, Andrea, Grecchi, Cecilia, Karaiskos, Ilias, Le Bihan, Clément, Mercier, Toine, Mortensen, Klaus L., Peghin, Maddalena, Rebuffi, Chiara, Tejada, Sofia, Vena, Antonio, Zuccaro, Valentina, Scudeller, Luigia, and Calandra, Thierry

Published
2024
Full Text
View/download PDF

14. Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP)

Author

Steinbeis, Fridolin, Thibeault, Charlotte, Steinbrecher, Sarah, Ahlgrimm, Yvonne, Haack, Ira an, August, Dietrich, Balzuweit, Beate, Bellinghausen, Carla, Berger, Sarah, Chaplinskaya-Sobol, Irina, Cornely, Oliver, Doeblin, Patrick, Endres, Matthias, Fink, Claudia, Finke, Carsten, Frank, Sandra, Hanß, Sabine, Hartung, Tim, Hellmuth, Johannes Christian, Herold, Susanne, Heuschmann, Peter, Heyckendorf, Jan, Heyder, Ralf, Hippenstiel, Stefan, Hoffmann, Wolfgang, Kelle, Sebastian Ulrich, Knape, Philipp, Koehler, Philipp, Kretzler, Lucie, Leistner, David Manuel, Lienau, Jasmin, Lorbeer, Roberto, Lorenz-Depiereux, Bettina, Lüttke, Constanze Dorothea, Mai, Knut, Merle, Uta, Meyer-Arndt, Lil Antonia, Miljukov, Olga, Muenchhoff, Maximilian, Müller-Plathe, Moritz, Neuhann, Julia, Neuhauser, Hannelore, Nieters, Alexandra, Otte, Christian, Pape, Daniel, Pinto, Rafaela Maria, Pley, Christina, Pudszuhn, Annett, Reuken, Philipp, Rieg, Siegberg, Ritter, Petra, Rohde, Gernot, Rönnefarth, Maria, Ruzicka, Michael, Schaller, Jens, Schmidt, Anne, Schmidt, Sein, Schwachmeyer, Verena, Schwanitz, Georg, Seeger, Werner, Stahl, Dana, Stobäus, Nicole, Stubbe, Hans Christian, Suttorp, Norbert, Temmesfeld, Bettina, Thun, Sylvia, Triller, Paul, Trinkmann, Frederik, Vadasz, Istvan, Valentin, Heike, Vehreschild, Maria, von Kalle, Christof, von Lilienfeld-Toal, Marie, Weber, Joachim, Welte, Tobias, Wildberg, Christian, Wizimirski, Robert, Zvork, Saskia, Sander, Leif Erik, Vehreschild, Janne, Zoller, Thomas, Kurth, Florian, and Witzenrath, Martin

Published
2024
Full Text
View/download PDF

16. Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study

Author

Egger, Matthias, Salmanton-García, Jon, Barac, Aleksandra, Gangneux, Jean-Pierre, Guegan, Hélène, Arsic-Arsenijevic, Valentina, Matos, Tadeja, Tomazin, Rok, Klimko, Nikolai, Bassetti, Matteo, Hammarström, Helena, Meijer, Eelco F. J., Meis, Jacques F., Prattes, Juergen, Krause, Robert, Resat Sipahi, Oguz, Scharmann, Ulrike, White, P. Lewis, Desoubeaux, Guillaume, García-Rodríguez, Julio, Garcia-Vidal, Carolina, Martín-Pérez, Sonia, Ruiz, Maite, Tumbarello, Mario, Talento, Alida Fe, Rogers, Benedict, Lagrou, Katrien, van Praet, Jens, Arikan-Akdagli, Sevtap, Arendrup, Maiken C., Koehler, Philipp, Cornely, Oliver A., and Hoenigl, Martin

Published
2023
Full Text
View/download PDF

18. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

Author

Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, da Silva, Maria Gomes, Glenthøj, Andreas, van Doesum, Jaap, Bilgin, Yavuz M, López-García, Alberto, Itri, Federico, Rodrigues, Raquel Nunes, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Venemyr, Caroline Berg, van Praet, Jens, Jaksic, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila-Valls, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola, Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José-Ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, di Blasi, Roberta, de Almedia, Joyce Marques, Dargenio, Michelina, Biernat, Monika M, Sciumè, Mariarita, de Ramón, Cristina, de Jonge, Nick, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenović, Miloš, Liévin, Raphaël, Hanáková, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, Cornely, Oliver A, Serrano, Laura, Susana, José-María Ribera-Santa, Meletiadis, Joseph, Tsirigotis, Panagiotis, Coppola, Nicola, Mikulska, Malgorzata, Erben, Nurettin, Besson, Caroline, Merelli, Maria, González-López, Tomás-José, Loureiro-Amigo, Jorge, García-Vidal, Carolina, de Kort, Elizabeth, Cuccaro, Annarosa, Zompi, Sofia, Reizine, Florian, Finizio, Olimpia, Duléry, Rémy, Calbacho, Maria, Abu-Zeinah, Ghaith, and Malak, Sandra

Subjects
Biotechnology, Emerging Infectious Diseases, Biodefense, Immunization, Infectious Diseases, Lung, Vaccine Related, Cancer, Prevention, Good Health and Well Being, Adult, Humans, COVID-19, SARS-CoV-2, COVID-19 Testing, Hematologic Neoplasms, Antibodies, Monoclonal, Antiviral Agents, Antibodies, Viral, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.

Published
2022

19. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Author

Abdel-Malek, Michael, Adelglass, Jeffrey, Alpizar, Sady Armad, Anderson, Duane, Andrews, Charles P., Askling, Helena Hervius, Baker, Jeffrey B., Baron, Mira, Barranco-Santana, Elizabeth A., Beckes, John, Bergthold, James H., Bosson, Peter, Buntinx, Erik, Bush, Larry Marc, Butuk, David J., Cartagena Ayala, Edgardo F., Choi, Hee Jung, Choi, Jung Hyun, Choi, Won Suk, Choi, Young Hwa, Clark, James R., Cornely, Oliver A., Cox, Steve E., Daboul, Nizar, De La Cruz, Luis Ignacio, De Silva, Pamela, Degen, Olaf, Ebuh, Valentine, Elzi, Stanton R., Fiel, Thomas, Fitzgibbons, William Patrick, Fraser, Neil J., Freeman, George Hartley, Galloway, Christopher, Garcia-Huidobro, Diego, Garza, Juan Carlos, George, Anil, Griffin, Carl Patrick, Guduri, Sridhar, Guner, Hatice Rahmet, Gunner, Elizabeth, Hanabergh, Enrique, Harper, Charles Harold, Harris, Kathleen, Hemmersmeier, John Matthew, Hill, John M., Huang, Ching-Tai, Huang, Kuo-Chin, Huberty, Chad Roger, Image, Bejamin James, Jandl, Margret, Johnston, William Henry, Jr., Kamerbeek, Jackie Marie, Karabay, Oguz, Ko, Jae-Hoon, Koksal, Iftihar, Kwon, Ki Tae, Leah, Amber, Lee, Dong-Gun, Lee, Jacob, Lenzmeier, Thomas C., Loh, Denissa, Lupercio, Rafael, Luts, Andes Erik, Lutz, Thomas, Martinez, Jose, Mayer, Renae, Miller, Vicki, Morales-Ramirez, Javier O., Munoz, Manuel, Navarro, Jesus Ovidio, Odekirk, Larry Lee, Odia, Patrick, Odio, Alberto J., O'Sullivan, Matthew, Patel, Minesh Arun, Pelayo, Enrique, Perez Cortes, Carlos, Pervaiz, Syed, Probst, Jared, Quinn, Dean Richard, Rigonan, Kathryn R., Rosario-Matos, Nicolas, Rosen, Jeffrey Bruce, Sannesten, Andrej, Schaefer, Axel, Schellberg, Sven, Sharma, Manjoo, Sher, Lawrence D., Shi, Hyejin, Shockey, Gerald R., Singh, Raj, Sjoberg, Folke, Smith, Brian, Smith, Christohper A., Smith, Deon, Smith, Susan Elizabeth, Song, Joon Young, Staben, Jonathan, Steil, Kenneth, Su, Chien-Tien, Ünal, Serhat, Wie, Seong-Heong, Wijewardane, Priyantha, Williams, Michael John, Wolf, Thomas A., Yang, Yi-Ching, Yeom, Joon Sup, Platt, Heather L, Bruno, Christopher, Barranco-Santana, Elizabeth A, Grijalva, Carlos G, Orenstein, Walter A, Morgan, Leslie, Fernsler, Doreen, Xu, Weifeng, Waleed, Muhammad, Li, Jianing, and Buchwald, Ulrike K

Published
2024
Full Text
View/download PDF

20. Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort Study

Author

Salmanton-García, Jon, Cornely, Oliver A., Stemler, Jannik, Barać, Aleksandra, Steinmann, Jörg, Siváková, Alena, Akalin, Emin Halis, Arikan-Akdagli, Sevtap, Loughlin, Laura, Toscano, Cristina, Narayanan, Manjusha, Rogers, Benedict, Willinger, Birgit, Akyol, Deniz, Roilides, Emmanuel, Lagrou, Katrien, Mikulska, Malgorzata, Denis, Blandine, Ponscarme, Diane, Scharmann, Urlike, Azap, Alpay, Lockhart, Deborah, Bicanic, Tihana, Kron, Florian, Erben, Nurettin, Rautemaa-Richardson, Riina, Goodman, Anna L., Garcia-Vidal, Carolina, Lass-Flörl, Cornelia, Gangneux, Jean-Pierre, Taramasso, Lucia, Ruiz, Maite, Schick, Yael, Van Wijngaerden, Eric, Milacek, Christopher, Giacobbe, Daniele Roberto, Logan, Clare, Rooney, Emily, Gori, Andrea, Akova, Murat, Bassetti, Matteo, Hoenigl, Martin, and Koehler, Philipp

Published
2024
Full Text
View/download PDF

21. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

Author

Stemler, Jannik, Yeghiazaryan, Lusine, Stephan, Christoph, Mohn, Kristin Greve-Isdahl, Carcas-Sansuan, Antonio-José, Rodriguez, Esperanza Romero, Moltó, José, Mitxeltorena, Itziar Vergara, Welte, Tobias, Zablockienė, Birutė, Akova, Murat, Bethe, Ullrich, Heringer, Sarah, Salmanton-García, Jon, Jeck, Julia, Tischmann, Lea, Zarrouk, Marouan, Cüppers, Arnd, Biehl, Lena M., Grothe, Jan, Mellinghoff, Sibylle C., Nacov, Julia A., Neuhann, Julia M., Sprute, Rosanne, Frías-Iniesta, Jesús, Negi, Riya, Gaillard, Colette, Saini, Gurvin, León, Alejandro García, Mallon, Patrick W.G., Lammens, Christine, Hotterbeekx, An, Loens, Katherine, Malhotra-Kumar, Surbhi, Goossens, Herman, Kumar-Singh, Samir, König, Franz, Posch, Martin, Koehler, Philipp, and Cornely, Oliver A.

Published
2024
Full Text
View/download PDF

25. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

Author

Hoenigl, Martin, Sprute, Rosanne, Arastehfar, Amir, Perfect, John R, Lass-Flörl, Cornelia, Bellmann, Romuald, Prattes, Juergen, Thompson, George R, Wiederhold, Nathan P, Al Obaidi, Mohanad M, Willinger, Birgit, Arendrup, Maiken C, Koehler, Philipp, Oliverio, Matteo, Egger, Matthias, Schwartz, Ilan S, Cornely, Oliver A, Pappas, Peter G, and Krause, Robert

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Antimicrobial Resistance, Infectious Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Antifungal Agents, Candida, Candidiasis, Candidiasis, Invasive, Drug Resistance, Fungal, Drugs, Investigational, Humans, Microbial Sensitivity Tests, Antimycotic, antiinfective, resistance, activity, trials, APX001, CD101, SCY-078, manogepix, fosmanogepix, ibrexafungerp, rezafungin, MAT2203, oteseconazole, VT-1161, ATI-2307, VL-2397, NP-339, miltefosine, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy, Oncology and carcinogenesis, Pharmacology and pharmaceutical sciences
Abstract

IntroductionThe epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more promising than ever and is enriched with repurposed drugs and agents that have new mechanisms of action. Despite progress, unmet needs in the treatment of invasive candidiasis remain, and there are still too few antifungals that can be administered orally or that have CNS penetration.Areas coveredThe authors shed light on those antifungal agents active against Candida that are in early- and late-stage clinical development. Mechanisms of action and key pharmacokinetic and pharmacodynamic properties are discussed. Insights are offered on the potential future roles of the investigational agents MAT-2203, oteseconazole, ATI-2307, VL-2397, NP-339, and the repurposed drug miltefosine.Expert opinionIbrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of Candida infections (including those caused by multiresistant Candida spp). Rezafungin, an echinocandin with an extended half-life allowing for once weekly administration, will be particularly valuable for outpatient treatment and prophylaxis. Despite this, there is an urgent need to garner clinical data on investigational drugs, especially in the current rise of azole-resistant and multidrug-resistant Candida spp.

Published
2022

26. Mapping the path to excellence: Evaluation of the diagnostic and treatment tools for invasive fungal infections in the balkans

Author

Dumitru, Irina-Magdalena, Stathi, Angeliki, Mandros, Charalampos, Travar, Maja, Milobratović, Danica, Mantzana, Paraskevi, Zaharia, Mihaela, Ostojić, Alen, Chatzimsochou, Athanasios, Tonkić, Marija, Otašević, Suzana, Jovanović, Danijela, Vukosavljević, Nikola, Bukovski, Suzana, Philipova, Ivva, Laura, Vlad Jeni, Savić, Aleksandar, Lupse, Mihaela, Manuela, Arbune, Dimova, Diana, Cviljević, Sabina, Orfanidou, Maria, Paramythiotou, Elisabeth, Cheran, Cristina Alexandra, Gartzonika, Konstantina, Skvarc, Miha, Nikolcheva-Todorova, Lidiya, Velikova, Tsvetelina, Panopoulou, Maria, Tihic, Nijaz, Bibić, Tamara, Tomic, Viktorija, Daniela, Serban Elena, Donchev, Krasimir, Sular, Floredana, Moroti, Ruxandra, Voichiţa, Lăzureanu Elena, Valković, Toni, Maraki, Sofija, Pantić, Nikola, Barać, Aleksandra, Mano, Vasilika, Dedeić-Ljubović, Amela, Malkodanski, Ivan, Jaksić, Ozren, Gkentzi, Despoina, Mitrović, Mirjana, Munteanu, Oxana, Šišević, Dijana, Stojanoski, Zlate, Popescu, Oana, Todorović, Jelena, Cornely, Oliver A., and Salmanton-García, Jon

Published
2024
Full Text
View/download PDF

27. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM

Author

Chang, Christina C, Harrison, Thomas S, Bicanic, Tihana A, Chayakulkeeree, Methee, Sorrell, Tania C, Warris, Adilia, Hagen, Ferry, Spec, Andrej, Oladele, Rita, Govender, Nelesh P, Chen, Sharon C, Mody, Christopher H, Groll, Andreas H, Chen, Yee-Chun, Lionakis, Michail S, Alanio, Alexandre, Castañeda, Elizabeth, Lizarazo, Jairo, Vidal, José E, Takazono, Takahiro, Hoenigl, Martin, Alffenaar, Jan-Willem, Gangneux, Jean-Pierre, Soman, Rajeev, Zhu, Li-Ping, Bonifaz, Alexandro, Jarvis, Joseph N, Day, Jeremy N, Klimko, Nikolai, Salmanton-García, Jon, Jouvion, Grégory, Meya, David B, Lawrence, David, Rahn, Sebastian, Bongomin, Felix, McMullan, Brendan J, Sprute, Rosanne, Nyazika, Tinashe K, Beardsley, Justin, Carlesse, Fabianne, Heath, Christopher H, Ayanlowo, Olusola O, Mashedi, Olga M, Queiroz-Telles Filho, Flavio, Hosseinipour, Mina C, Patel, Atul K, Temfack, Elvis, Singh, Nina, Cornely, Oliver A, Boulware, David R, Lortholary, Olivier, Pappas, Peter G, and Perfect, John R

Published
2024
Full Text
View/download PDF

31. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time

Author

Kenny, Grace, O’Reilly, Sophie, Wrigley Kelly, Neil, Negi, Riya, Gaillard, Colette, Alalwan, Dana, Saini, Gurvin, Alrawahneh, Tamara, Francois, Nathan, Angeliadis, Matthew, Garcia Leon, Alejandro Abner, Tinago, Willard, Feeney, Eoin R., Cotter, Aoife G., de Barra, Eoghan, Yousif, Obada, Horgan, Mary, Doran, Peter, Stemler, Jannik, Koehler, Philipp, Cox, Rebecca Jane, O’Shea, Donal, Olesen, Ole F., Landay, Alan, Hogan, Andrew E., Lelievre, Jean-Daniel, Gautier, Virginie, Cornely, Oliver A., and Mallon, Patrick W. G.

Published
2023
Full Text
View/download PDF

32. Staphylococcus aureus surgical site infection rates in 5 European countries

Author

Mellinghoff, Sibylle C., Bruns, Caroline, Albertsmeier, Markus, Ankert, Juliane, Bernard, Louis, Budin, Sofia, Bataille, Camille, Classen, Annika Y., Cornely, Florian B., Couvé-Deacon, Elodie, Fernandez Ferrer, Maria, Fortún, Jesús, Galar, Alicia, Grill, Eva, Guimard, Thomas, Hampl, Jürgen A., Wingen-Heimann, Sebastian, Horcajada, Juan P., Köhler, Felix, Koll, Carolin, Mollar, Joan, Muñoz, Patricia, Pletz, Mathias W., Rutz, Jule, Salmanton-García, Jon, Seifert, Harald, Serracino-Inglott, Ferdinand, Soriano, Alex, Stemler, Jannik, Vehreschild, Janne J., Vilz, Tim O., Naendrup, Jan-Hendrik, Cornely, Oliver A., and Liss, Blasius J.

Published
2023
Full Text
View/download PDF

33. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Author

Marchesi, Francesco, Salmanton-García, Jon, Buquicchio, Caterina, Itri, Federico, Besson, Caroline, Dávila-Valls, Julio, Martín-Pérez, Sonia, Fianchi, Luana, Rahimli, Laman, Tarantini, Giuseppe, Grifoni, Federica Irene, Sciume, Mariarita, Labrador, Jorge, Cordoba, Raul, López-García, Alberto, Fracchiolla, Nicola S., Farina, Francesca, Ammatuna, Emanuele, Cingolani, Antonella, García-Bordallo, Daniel, Gräfe, Stefanie K., Bilgin, Yavuz M., Dargenio, Michelina, González-López, Tomás José, Guidetti, Anna, Lahmer, Tobias, Lavilla-Rubira, Esperanza, Méndez, Gustavo-Adolfo, Prezioso, Lucia, Schönlein, Martin, Van Doesum, Jaap, Wolf, Dominik, Hersby, Ditte Stampe, Magyari, Ferenc, Van Praet, Jens, Petzer, Verena, Tascini, Carlo, Falces-Romero, Iker, Glenthøj, Andreas, Cornely, Oliver A., and Pagano, Livio

Published
2023
Full Text
View/download PDF

34. Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study

Author

Giacobbe, Daniele Roberto, Prattes, Juergen, Wauters, Joost, Dettori, Silvia, Signori, Alessio, Salmanton-García, Jon, Maertens, Johan, Bourgeois, Marc, Reynders, Marijke, Rutsaert, Lynn, Van Regenmortel, Niels, Lormans, Piet, Feys, Simon, Klimko, Nikolay, Shadrivova, Olga, Cornely, Oliver A, Rautemaa-Richardson, Riina, Koehler, Philipp, Lagrou, Katrien, Bassetti, Matteo, and Hoenigl, Martin

Subjects
Infectious Diseases, Rare Diseases, Lung, Good Health and Well Being, Aspergillus, Bronchoalveolar Lavage Fluid, COVID-19, Critical Illness, Galactose, Humans, Intensive Care Units, Invasive Pulmonary Aspergillosis, Mannans, Mycology, Prognosis, Pulmonary Aspergillosis, Sensitivity and Specificity, CAPA, GM, biomarker, galactomannan, BALF, ECMM-CAPA Study Group, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Microbiology
Abstract

Critically ill patients with coronavirus disease 2019 (COVID-19) may develop COVID-19-associated pulmonary aspergillosis (CAPA), which impacts their chances of survival. Whether positive bronchoalveolar lavage fluid (BALF) mycological tests can be used as a survival proxy remains unknown. We conducted a post hoc analysis of a previous multicenter, multinational observational study with the aim of assessing the differential prognostic impact of BALF mycological tests, namely, positive (optical density index of ≥1.0) BALF galactomannan (GM) and positive BALF Aspergillus culture alone or in combination for critically ill patients with COVID-19. Of the 592 critically ill patients with COVID-19 enrolled in the main study, 218 were included in this post hoc analysis, as they had both test results available. CAPA was diagnosed in 56/218 patients (26%). Most cases were probable CAPA (51/56 [91%]) and fewer were proven CAPA (5/56 [9%]). In the final multivariable model adjusted for between-center heterogeneity, an independent association with 90-day mortality was observed for the combination of positive BALF GM and positive BALF Aspergillus culture in comparison with both tests negative (hazard ratio, 2.53; 95% CI confidence interval [CI], 1.28 to 5.02; P = 0.008). The other independent predictors of 90-day mortality were increasing age and active malignant disease. In conclusion, the combination of positive BALF GM and positive BALF Aspergillus culture was associated with increased 90-day mortality in critically ill patients with COVID-19. Additional study is needed to explore the possible prognostic value of other BALF markers.

Published
2022

35. COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP

Author

Busca, Alessandro, Salmanton-García, Jon, Corradini, Paolo, Marchesi, Francesco, Cabirta, Alba, Di Blasi, Roberta, Dulery, Remy, Lamure, Sylvain, Farina, Francesca, Weinbergerová, Barbora, Batinić, Josip, Nordlander, Anna, López-García, Alberto, Drgoňa, Ľuboš, Espigado-Tocino, Ildefonso, Falces-Romero, Iker, García-Sanz, Ramón, García-Vidal, Carolina, Guidetti, Anna, Khanna, Nina, Kulasekararaj, Austin, Maertens, Johan, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A, and Pagano, Livio

Subjects
Prevention, Infection, Good Health and Well Being, COVID-19, Humans, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes
Abstract

The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.

Published
2022

39. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author

Martín-Vallejo, Francisco Javier, Zdziarski, Przemyslaw, Zarrinfer, Hossein, Wittig, Jana, Win, Sein, Wai-Man, Vivien, Víšek, Benjamín, Vinh, Donald C., Vehreschild, Maria, Varricchio, Gina, Tsirigotis, Panagiotis, Torres-Tienza, Ana, Tanase, Alina Daniela, Tafuri, Agostino, Stamouli, Maria, Sramek, Jiří, Soussain, Carole, Shirinova, Ayten, Schubert, Jörg, Schalk, Enrico, Salehi, Mohammad Reza, Saleh, Modar, Rosati, Giorgio, Roldán, Elisa, Reizine, Florian, Rêgo, Mayara, Regalado-Artamendi, Isabel, Popova, Marina, Pinto, Fernando, Philippe, Laure, Orth, Hans Martin, Ommen, Hans-Beier, Obr, Aleš, Núñez-Martín-Buitrago, Lucía, Noël, Nicolas, Neuhann, Julia, Nadali, Gianpaolo, Nacov, Julia A., Munhoz Alburquerque, Ana M., Mitra, Maria Enza, Mikulska, Malgorzata, Mellinghoff, Sibylle, Mechtel, Ben, Martín-González, Juan-Alberto, Malak, Sandra, Loureiro-Amigo, Jorge, Lorenzo De La Peña, Lisset, Liberti, Giulia, Landau, Marianne, Lacej, Ira, Kolditz, Martin, Kho, Chi Shan, Khedr, Reham Abdelaziz, Karthaus, Meinolf, Karlsson, Linda Katharina, Jiménez-Lorenzo, María-Josefa, Izuzquiza, Macarena, Hoell-Neugebauer, Baerbel, Herbrecht, Raoul, Heath, Christopher H., Guolo, Fabio, Grothe, Jan, Giordano, Antonio, Gerasymchuk, Sergey, García-Sanz, Ramón, García-Poutón, Nicole, Funke, Vaneuza Araújo Moreira, Fung, Monica, Flasshove, Charlotte, Fianchi, Luana, Essame, Jenna, Egger, Matthias, Drenou, Bernard, Dragonetti, Giulia, Desole, Maximilian, Della Pepa, Roberta, Deau Fischer, Bénédicte, De Kort, Elizabeth, De Cabo, Erik, Danion, François, Daguindau, Etienne, Cushion, Tania, Cremer, Louise, Criscuolo, Marianna, Cordini, Gregorio, Cingolani, Antonella, Ciceri, Fabio, Chowdhury, Fazle Rabbi, Chelysheva, Ekaterina, Chauchet, Adrien, Chai, Louis Yi Ann, Ceesay, M. Mansour, Busch, Elena, Brehon, Mathias, Borducchi, Davimar M.M., Booth, Stephen, Bologna, Serge, Berg Venemyr, Caroline, Bailén-Almorox, Rebeca, Antoniadou, Anastasia, Anastasopoulou, Amalia N., Altuntaş, Fevzi, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes Da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, Vian Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola S., Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-VUKIČEVIĆ, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S., Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques De Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Shumilov, Evgenii, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Quattrone, Martina, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

41. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials

Author

Thompson, George R, III, Soriano, Alex, Honore, Patrick M, Bassetti, Matteo, Cornely, Oliver A, Kollef, Marin, Kullberg, Bart Jan, Pullman, John, Hites, Maya, Fortún, Jesús, Horcajada, Juan P, Kotanidou, Anastasia, Das, Anita F, Sandison, Taylor, Aram, Jalal A, Vazquez, Jose A, and Pappas, Peter G

Published
2024
Full Text
View/download PDF

43. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart JA, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Antifungal Agents, Aspergillosis, Bronchoalveolar Lavage Fluid, Humans, Immunocompromised Host, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis, Mannans, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2021

44. EQUAL Score Scedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence

Author

Stemler, Jannik, Lackner, Michaela, Chen, Sharon C-A, Hoenigl, Martin, and Cornely, Oliver A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Clinical Research, Infection, Antifungal Agents, Guideline Adherence, Humans, Invasive Fungal Infections, Mycology, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

BackgroundInvasive scedosporiosis and lomentosporiosis are life-threatening fungal infections in immunocompromised patients with complex diagnostic and treatment patterns.ObjectivesTo develop a scoring tool to facilitate and quantify adherence to current guideline recommendations for diagnosis, treatment and follow-up of invasive scedosporiosis and lomentosporiosis.MethodsExperts from European Confederation of Medical Mycology (ECMM) excellence centres reviewed current guidelines for scedosporiosis and lomentosporiosis. Recommendations for diagnosis, treatment and follow-up were summarized, assembled and weighted according to their strength of recommendation and level of evidence (strongly recommended = 3 points; moderately recommended = 2 points; marginally recommended = 1 point; recommended against = 0 points). Additional items considered of high importance for clinical management were also weighted.ResultsA total of 170 recommendations were identified. A 21-item tool was developed and embedded into the EQUAL score card. Nine items for diagnosis with 18 achievable points were assembled. For treatment, three general recommendation items with a maximal score of 9 were identified, while for specific antifungal treatment the two fungal pathogens were separated. Three and four items were established for scedosporiosis and lomentosporiosis, respectively, with a maximum achievable score of 3 due to the separation of different treatment options with the maximum point value of 3 for voriconazole-based treatment. Follow-up comprised two items (4 points maximum). Key recommendations for clinical outcome were weighted accordingly.ConclusionsWe propose the EQUAL Score Scedosporiosis/Lomentosporiosis to quantify adherence to current guideline recommendations for management of these rare infections. The score remains to be validated in real-life patient cohorts and correlated with patient outcome.

Published
2021

45. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology

Author

Thompson, George R, Le, Thuy, Chindamporn, Ariya, Kauffman, Carol A, Alastruey-Izquierdo, Ana, Ampel, Neil M, Andes, David R, Armstrong-James, Darius, Ayanlowo, Olusola, Baddley, John W, Barker, Bridget M, Lopes Bezerra, Leila, Buitrago, Maria J, Chamani-Tabriz, Leili, Chan, Jasper FW, Chayakulkeeree, Methee, Cornely, Oliver A, Cunwei, Cao, Gangneux, Jean-Pierre, Govender, Nelesh P, Hagen, Ferry, Hedayati, Mohammad T, Hohl, Tobias M, Jouvion, Grégory, Kenyon, Chris, Kibbler, Christopher C, Klimko, Nikolai, Kong, David CM, Krause, Robert, Lee Lee, Low, Meintjes, Graeme, Miceli, Marisa H, Rath, Peter-Michael, Spec, Andrej, Queiroz-Telles, Flavio, Variava, Ebrahim, Verweij, Paul E, Schwartz, Ilan S, and Pasqualotto, Alessandro C

Subjects
Infectious Diseases, Prevention, Emerging Infectious Diseases, Vaccine Related, Biodefense, Infection, Good Health and Well Being, Animals, Clinical Decision-Making, Consensus, Endemic Diseases, Europe, Global Health, Guidelines as Topic, Humans, International Cooperation, Mycoses, Risk Factors, Clinical Sciences, Medical Microbiology, Public Health and Health Services, Microbiology
Abstract

The global burden of the endemic mycoses (blastomycosis, coccidioidomycosis, emergomycosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis, and talaromycosis) continues to rise yearly and these infectious diseases remain a leading cause of patient morbidity and mortality worldwide. Management of the associated pathogens requires a thorough understanding of the epidemiology, risk factors, diagnostic methods and performance characteristics in different patient populations, and treatment options unique to each infection. Guidance on the management of these infections has the potential to improve prognosis. The recommendations outlined in this Review are part of the "One World, One Guideline" initiative of the European Confederation of Medical Mycology. Experts from 23 countries contributed to the development of these guidelines. The aim of this Review is to provide an up-to-date consensus and practical guidance in clinical decision making, by engaging physicians and scientists involved in various aspects of clinical management.

Published
2021

47. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Author

Hoenigl, Martin, Sprute, Rosanne, Egger, Matthias, Arastehfar, Amir, Cornely, Oliver A, Krause, Robert, Lass-Flörl, Cornelia, Prattes, Juergen, Spec, Andrej, Thompson, George R, Wiederhold, Nathan, and Jenks, Jeffrey D

Subjects
Antimicrobial Resistance, Infectious Diseases, Emerging Infectious Diseases, Biodefense, Prevention, Vaccine Related, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Infection, Pharmacology & Pharmacy, Pharmacology and Pharmaceutical Sciences
Abstract

The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and constraints in administration routes. Despite the need for more antifungal drug options, no new classes of antifungal drugs have become available over the last 2 decades, and only one single new agent from a known antifungal class has been approved in the last decade. Nevertheless, there is hope on the horizon, with a number of new antifungal classes in late-stage clinical development. In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in development, including fosmanogepix (a novel Gwt1 enzyme inhibitor), ibrexafungerp (a first-in-class triterpenoid), olorofim (a novel dihyroorotate dehydrogenase enzyme inhibitor), opelconazole (a novel triazole optimized for inhalation), and rezafungin (an echinocandin designed to be dosed once weekly). We focus on the mechanism of action and pharmacokinetics, as well as the spectrum of activity and stages of clinical development. We also highlight the potential future role of these drugs and unmet needs.

Published
2021

48. Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics

Author

Busch, Martin, Seifert, Ulrike, Widmer, Andreas, Nagao, Miki, Rello, Jordi, Todorova, Tatina, Cviljević, Sabina, Heath, Christopher H., Jančorienė, Ligita, Fischer, Thea Koelsen, Orth, Hans Martin, Johansen, Isik Somuncu, Doymaz, Mehmet, Tragiannidis, Athanasios, Löscher, Thomas, Xu, Jin-Fu, Husa, Petr, Oteo, José Antonio, Issack, Mohammad I., Zeitlinger, Markus, Le Grand, Roger, Zdziarski, Przemysław, Demirkan, Fatih, Amador, Paloma Merino, García-Lozano, Tomás, Cao, Qing, Vázquez, Lourdes, Caeiro, Juan Pablo, Hermans, Peter, Nahrwar, Shahroch, Avsar, Korkut, Kumar, Deepak, Fernández, Norma, Mardani, Masoud, Segal, Esther, Pan, Angelo, Gkentzi, Despoina, Gioula, Georgia, Cortés, Jorge Alberto, Oliveira, Joaquim, van Damme, Pierre, Bin Mohd Zaili, Mohd Zaki, Antinori, Spinello, Zablockienė, Birutė, Papazisis, Georgios, Aneke, Chioma Inyang, Valerio, Maricela, McConkey, Samuel, Aujayeb, Avinash, Azzini, Anna Maria, Roganović, Jelena, Greve-Isdahl Mohn, Kristin, Kremsner, Peter, Gkrania-Klotsas, Effrossyni, Corzo, Dora, Khanna, Nina, Smiatacz, Tomasz, Scheithauer, Simone, Merelli, Maria, Klempa, Boris, Vrḫovac, Radovan, Ruggiero, Antonio, Chaudhary, Pankaj, Maquera-Afaray, Julio, Ekkelenkamp, Miquel, Jindra, Pavel, Pantić, Nikola, Guerra, Gemma Jiménez, Weiss, Guenter, Roohi, Behrad, Argyropoulos, Christos D., Silfverdal, Sven Aprne, van Praet, Jens, Bal, Zumrut Sahbudak, Kanj, Souha, Young, Barnaby, Pana, Zoi Dorothea, Roilides, Emmanuel, Stearns, Stephen C., Wauters, Joost, Baño, Jesús Rodríguez, Pletz, Mathias W., Travar, Maja, Kühn, Steven, Riera, Fernando, Cornely, Daniel, Laura, Vlad Jeni, Koehler, Philipp, Eley, Brian, Nair, Pravin K., Ciesek, Sandra, Olaru, Ioana Diana, Marques, Laura, Pontali, Emanuele, Naunheim, Alexandra, Lieb, Adrian, Gerhard, Markus, Farooqi, Joveria Qais, Turtle, Lance, Méndez, Gustavo Adolfo, Cox, Rebecca Jane, Goodman, Nigel, Caceca, Billie, Pemán, Javier, Dawood, Halima, Askling, Helena Hervius, Fomsgaard, Anders, Hernández, Alejandra Calderón, Staehelin, Cornelia, Liu, Chia-Ying, Icardi, Giancarlo, Castagnola, Elio, Salzer, Helmut J.F., Lundgren, Jens, Javadli, Samir, Forghieri, Fabio, Salmanton-García, Jon, Wipfler, Pauline, Leckler, Janina, Nauclér, Pontus, Mallon, Patrick W., Bruijning-Verhagen, Patricia C.J.L., Schmitt, Heinz-Joseph, Bethe, Ullrich, Olesen, Ole F., Stewart, Fiona A., Albus, Kerstin, and Cornely, Oliver A.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results